Evidence map›Paper›PMID 35053380›Full record

ArticleCells2022

Phosphorylation-Induced Ubiquitination and Degradation of PXR through CDK2-TRIM21 Axis.

Mengyao Qin, Yu Xin, Yong Bian, Xuan Yang, Tao Xi, Jing Xiong

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 18 citations in OpenAlex.

  1. Physiological Functions and Pathological Roles of PXR.Journal of the Endocrine Society · 2025
    Review
  2. Review
  3. Article
  4. Nonspecific Inhibition of IL6 Family Cytokine Signalling by Soluble gp130.International journal of molecular sciences · 2024
    Article
  5. Article
  6. Article
  7. [Juglone induces proliferation inhibition and apoptosis of cervical cancer cellsNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2022
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Mengyao QinDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yu XinDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Yong BianLaboratory Animal Center, Nanjing University of Chinese Medicine, Nanjing 210023, China.
Xuan YangDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
Tao XiResearch Center of Biotechnology, School of Life Science and Technology, China Pharmaceutical University, Nanjing 210009, China.
Jing XiongDepartment of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.ORCID 0000-0002-9712-6771
China Pharmaceutical University · CNNanjing University of Chinese Medicine · CN

Funding

National Natural Science Foundation of China 82070883
6 · The paper itself

Abstract

Pregnane X receptor (PXR) is a member of the nuclear receptor superfamily that is activated by a variety of endogenous metabolites or xenobiotics. Its downstream target genes are involved in metabolism, inflammation and processes closely related to cancer. However, the stability regulation of PXR protein resulting from post-translational modification is still largely undefined. In the present study, primary mouse hepatocytes, hepatoma HepG2 cells and HEK 293T cells were used to investigate gene expression and protein interactions. The role of kinases was evaluated by RNA interference and overexpression constructs with or without PXR phosphorylation site mutations. The activity of CYP3A4 and P-gp was determined by enzymatic and substrate accumulation assays. It was found that E3 ubiquitin ligase TRIM21 mediates the ubiquitination and degradation of PXR and plays an important role in regulating the activity of PXR. On this basis, PXR phosphorylation-associated kinases were evaluated regarding regulation of the stability of PXR. We found cyclin dependent kinase 2 (CDK2) exclusively phosphorylates PXR at Ser350, promotes its disassociation with Hsp90/DNAJC7, and leads to subsequent TRIM21-mediated PXR ubiquitination and degradation. As well-known CDK inhibitors, dinaciclib and kenpaullone stabilize PXR and result in elevated expression and activity of PXR-targeted DMETs, including carboxylesterases, CYP3A4 and P-gp. The suppressed degradation of PXR by CDK2 inhibitors denotes dinaciclib-induced promotion of PXR-targeted genes. The findings of CDK2-mediated PXR degradation indicate a wide range of potential drug-drug interactions during clinical cancer therapy using CDK inhibitors and imply an alternative direction for the development of novel PXR antagonists.

Indexed as

ProteolysisSignal TransductionUbiquitinationCyclic N-OxidesCyclin-Dependent Kinase 2Gene Expression RegulationHeat-Shock ProteinsHEK293 CellsHepatocytesHep G2 CellsHSP90 Heat-Shock ProteinsHumansIndolizinesMolecular ChaperonesPhosphorylationPhosphoserineCyclic N-OxidesCyclin-Dependent Kinase 2dinaciclibDNAJC7 protein, humanHeat-Shock ProteinsHSP90 Heat-Shock ProteinsIndolizinesMolecular ChaperonesPhosphoserinePregnane X ReceptorProteasome Endopeptidase ComplexProtein Kinase InhibitorsPyridinium CompoundsRibonucleoproteinsSS-A AntigenUbiquitincyclin dependent kinase 2dinaciclibdrug-metabolizing enzymes and transporterspregnane X receptortripartite motif containing 21ubiquitination

Identifiers

PMID35053380
PMCPMC8773821
OpenAlexW4205685178

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.